Literature DB >> 1387032

D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment.

M Laruelle1, G E Jaskiw, B K Lipska, B Kolachana, M F Casanova, J E Kleinman, D R Weinberger.   

Abstract

The antipsychotic effects of neuroleptic drugs are believed to be achieved by chronic blockade of dopaminergic transmission in the limbic system. Nevertheless, the effects of chronic (3-12 months) haloperidol administration on the dopaminergic transmission in the nucleus accumbens of rodents remains poorly understood. Studies of spontaneous locomotor activity (SLA), a behavioral measure related to limbic dopamine transmission, and of dopamine D2 receptor density in the nucleus accumbens after chronic oral haloperidol treatment have yielded conflicting results. We evaluated these indices after 8 months of parenteral administration of haloperidol decanoate. We report here that, after 8 months of parenteral treatment, SLA stays significantly decreased and D2 receptors in the nucleus accumbens exhibit the same up-regulation as in the striatum (about 50%). These results fail to support the notion of a different pattern of D2 receptor adaptation to neuroleptic treatment between the nucleus accumbens and the striatum. In contrast, dopamine D1 receptors were found to be unaffected in the nucleus accumbens but decreased in the striatum by 22% after 8 months of treatment. This observation could be relevant to the pathogenesis of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1387032     DOI: 10.1016/0006-8993(92)90421-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

Review 1.  Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Authors:  L Besret; A L Kendall; S B Dunnett
Journal:  J Anat       Date:  2000-05       Impact factor: 2.610

2.  Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Psychopharmacology (Berl)       Date:  2006-08-30       Impact factor: 4.530

Review 3.  Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications.

Authors:  A R Braun; M Laruelle; M M Mouradian
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.

Authors:  M S Lidow; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

5.  Behavioral and neurochemical changes in the dopaminergic system after repeated cocaine administration.

Authors:  L H Claye; H C Akunne; M D Davis; S DeMattos; K F Soliman
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

6.  Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.

Authors:  B Glenthøj
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.

Authors:  Jessica Deslauriers; Christian Desmarais; Philippe Sarret; Sylvain Grignon
Journal:  J Mol Neurosci       Date:  2012-09-14       Impact factor: 3.444

8.  Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.

Authors:  Kathryn M Gill; James M Cook; Michael M Poe; Anthony A Grace
Journal:  Schizophr Bull       Date:  2014-01-24       Impact factor: 9.306

9.  Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration.

Authors:  Wendy H Fasulo; Scott E Hemby
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

10.  An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states.

Authors:  R de Beaurepaire; A Labelle; D Naber; B D Jones; T R Barnes
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.